The FDA has proposed ending the use of a common ingredient found in many cold and allergy medicines — and some pharmacies ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

ACELYRIN, INC. (SLRN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily ...

The FDA designated 166 products under its breakthrough devices program in its most recent financial year, reversing the ...

Belski is especially bullish on small- and mid-cap equities, calling them “the golden child of the next decade. I think that ...

Donald Trump returning to the White House triggered new index records in the US, and major UK companies are likely to feel ...

Harvey Jones thought he was getting a bargain when he snapped up these too much-loved FTSE 100 dividend growth stocks. Now they're getting on his nerves. The post These 2 former stock market darlings ...

While the numbers slumped in Q3 2024, this was expected, especially as reported earnings absorbed Zantac related payouts. They are unlikely to impact full year figures, however. In the meantime ...

We will deliver our fully reinvigorated portfolio to market efficiently and maximise the considerable commercial potential, ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...